The cost-effectiveness and cost of treatment failures associated with systemic psoriasis therapies
- PMID: 16467021
- DOI: 10.1080/09546630500504754
The cost-effectiveness and cost of treatment failures associated with systemic psoriasis therapies
Abstract
Background: Psoriasis is difficult at times to treat and treatment failures are not uncommon regardless of approach. With the advent of expensive biologic therapies for psoriasis there is increasing discussion on the cost efficacy of a given systemic or biologic agent. An alternative and overlooked aspect of cost efficacy is the cost that accrues from treatment failures.
Methods: We review the literature and develop a model to analyze the cost-effectiveness and the cost of treatment failures per success for various systemic psoriasis agents using a 12-week treatment period.
Results: For continuous-dose agents, the cost-effectiveness results are: methotrexate $623, acitretin $2729, cyclosporine $2969, nUVB $3692, PUVA $4668, etanercept $16 312, and efalizumab $17 196. The cost of expected treatment failures to achieve one success for the same agents were: methotrexate $187, cyclosporine $505, PUVA $767, nUVB $1034, acitretin $1310, etanercept $8319, and efalizumab $12 897.
Conclusions: Methotrexate appears to be the most cost-effective agent for the treatment of severe psoriasis. However, greater efficacy can be achieved with cyclosporine and PUVA, albeit at a greater cost. Because of the high cost of treatment failures, access to a wide array of therapies and combination regimens should not be discouraged by physicians or insurers.
Similar articles
-
Systemic treatment for moderate to severe psoriasis: estimates of failure rates and direct medical costs in a north-eastern US managed care plan.J Dermatolog Treat. 2005 Feb;16(1):37-42. doi: 10.1080/09546630510025941. J Dermatolog Treat. 2005. PMID: 15897166
-
[Cost-effectiveness analysis comparing methotrexate with PUVA therapy for moderate-severe psoriasis in the sanitary area of Badajoz].Actas Dermosifiliogr. 2007 Jan-Feb;98(1):35-41. Actas Dermosifiliogr. 2007. PMID: 17374331 Spanish.
-
Paradoxical effects of cost reduction measures in managed care systems for treatment of severe psoriasis.Dermatol Online J. 2009 Apr 15;15(4):1. Dermatol Online J. 2009. PMID: 19450394
-
Estimated cost efficacy of systemic treatments that are approved by the US Food and Drug Administration for the treatment of moderate to severe psoriasis.J Am Acad Dermatol. 2015 Apr;72(4):589-98. doi: 10.1016/j.jaad.2014.11.028. Epub 2015 Jan 25. J Am Acad Dermatol. 2015. PMID: 25631851 Review.
-
Combination therapy to treat moderate to severe psoriasis.J Am Acad Dermatol. 2004 Mar;50(3):416-30. doi: 10.1016/j.jaad.2002.12.002. J Am Acad Dermatol. 2004. PMID: 14988684 Review.
Cited by
-
TNFAIP3 gene polymorphisms are associated with response to TNF blockade in psoriasis.J Invest Dermatol. 2012 Mar;132(3 Pt 1):593-600. doi: 10.1038/jid.2011.376. Epub 2011 Nov 24. J Invest Dermatol. 2012. PMID: 22113471 Free PMC article.
-
Treatment sequencing after failure of the first biologic in cost-effectiveness models of psoriasis: a systematic review of published models and clinical practice guidelines.Pharmacoeconomics. 2014 Apr;32(4):395-409. doi: 10.1007/s40273-014-0130-5. Pharmacoeconomics. 2014. PMID: 24469676 Free PMC article. Review.
-
Treatment costs of psoriasis in a tertiary-level clinic.BMC Health Serv Res. 2014 Aug 15;14:344. doi: 10.1186/1472-6963-14-344. BMC Health Serv Res. 2014. PMID: 25128268 Free PMC article.
-
Cost-Effectiveness Analysis of Psoriasis Treatment Modalities in Malaysia.Int J Health Policy Manag. 2019 Jul 1;8(7):394-402. doi: 10.15171/ijhpm.2019.17. Int J Health Policy Manag. 2019. PMID: 31441276 Free PMC article.
-
Biologicals and small molecules in psoriasis: A systematic review of economic evaluations.PLoS One. 2018 Jan 3;13(1):e0189765. doi: 10.1371/journal.pone.0189765. eCollection 2018. PLoS One. 2018. PMID: 29298315 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
